Cotización Kazia Therapeutics - KZIA

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

3.40

Postura de Compra

3.05

Postura de Venta

3.59

Volume Operado de la Acción

133,626

3.00 Rango del Día 3.64

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

11.317M

Precio Anterior

3.33

Precio de Apertura

3.64

Hora

3.35

Última hora de negociación

Volumen financiero

US$ 432,025

Precio Promedio Ponderado

3.2331

Volumen promedio (3 m)

Acciones en circulación

3,328,508

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.01

Beneficio por acción (BPA)

-6.15

turnover

Beneficio neto

-20.47M

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.kaziatherapeutics.com

Sede

Sydney, New South Wales, Aus

Fundado

Kazia Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KZIA. The last closing price for Kazia Therapeutics was US$3.33. Over the last year, Kazia Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Kazia Therapeutics currently has 3,328,508 shares in issue. The market capitalisation of Kazia Therapeutics is US$11.08 million. Kazia Therapeutics has a price to earnings ratio (PE ratio) of -0.01.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
NUKKNukkleus Inc	US$ 11.655 (738.49%)	174.07M
PRTGPortage Biotech Inc	US$ 8.8678 (172.86%)	36.23M
OPTXSyntec Optics Holdings Inc	US$ 3.55 (99.44%)	92.44M
PTPIPetros Pharmaceuticals Inc	US$ 0.4976 (86.37%)	63.38M
LUXHLuxUrban Hotels Inc	US$ 0.849899 (59.67%)	29.51M
VCNXVaccinex Inc	US$ 1.41 (-61.37%)	758.95k
TNYATenaya Therapeutics Inc	US$ 1.395 (-51.56%)	42.45M
ORKTOrangeKloud Technology Inc	US$ 2.14 (-41.85%)	2.29M
RVPHReviva Pharmaceuticals Holdings Inc	US$ 1.395 (-39.35%)	18.16M
DBGIDigital Brands Group Inc	US$ 2.46 (-37.88%)	805.23k
RIMEAlgorhythm Holdings Inc	US$ 0.0877 (8.27%)	1.13B
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.335 (-36.79%)	1.02B
GOEVCanoo Inc	US$ 0.118 (7.08%)	388.43M
NVDANVIDIA Corporation	US$ 130.39 (-1.22%)	259.4M
XTIAXTI Aerospace Inc	US$ 0.0442 (8.33%)	222.55M